^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HH185
i
Other names: HH185 , 3D-185, HH 185, HH-185, 3D185, 3D 185
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
3DMed, CSPC Pharma, HaiHe Biopharma
Drug class:
FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor, CSF-1R inhibitor
Related drugs:
4ms
A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
HH185
1year
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
FGFR (Fibroblast Growth Factor Receptor)
|
HH185
over1year
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
FGFR (Fibroblast Growth Factor Receptor)
|
HH185
over3years
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd.
Clinical • New P2 trial
|
FGFR (Fibroblast Growth Factor Receptor)
|
HH185
Share via
